

## **Product datasheet for TL505993V**

#### OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

## **Dcun1d1 Mouse shRNA Lentiviral Particle (Locus ID 114893)**

### **Product data:**

**Product Type:** shRNA Lentiviral Particles

**Product Name:** Dcun1d1 Mouse shRNA Lentiviral Particle (Locus ID 114893)

**Locus ID:** 114893

Synonyms: pTes3; Rp42; SCCRO; Tes3

Vector: pGFP-C-shLenti (TR30023)

Format: Lentiviral particles

Components: Dcun1d1 - Mouse shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1

scramble control), 0.5 ml each, >10^7 TU/ml.

**RefSeq:** BC020161, BC031666, BC037431, NM 001205361, NM 001205362, NM 033623, NM 033623.1,

NM 033623.2, NM 033623.3, NM 033623.4, NM 033623.5, NM 033623.6, NM 001205362.1,

NM 001205361.1, BC020161.1

UniProt ID: Q9QZ73

Summary: Part of an E3 ubiquitin ligase complex for neddylation. Promotes neddylation of cullin

components of E3 cullin-RING ubiquitin ligase complexes. Acts by binding to cullin-RBX1 complexes in the cytoplasm and promoting their nuclear translocation, enhancing recruitment of E2-NEDD8 (UBE2M-NEDD8) thioester to the complex, and optimizing the orientation of proteins in the complex to allow efficient transfer of NEDD8 from the E2 to the cullin substrates. Involved in the release of inhibitory effets of CAND1 on cullin-RING ligase E3

complex assembly and activity (By similarity). Acts also as an oncogene facilitating malignant transformation and carcinogenic in vivo (PubMed:20563250).[UniProtKB/Swiss-Prot Function]

**shRNA Design:** These shRNA constructs were designed against multiple splice variants at this gene locus. To

be certain that your variant of interest is targeted, please contact <u>techsupport@origene.com</u>. If you need a special design or shRNA sequence, please utilize our <u>custom shRNA service</u>.





# Performance Guaranteed:

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).